Treatment with a GLP−1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

European Neuropsychopharmacology

Volumn 27, Issue 11, 2017, Pages 1153-1162

  Mansur, Rodrigo B ^a,b   Zugman, Andre ^b   Ahmed, Juhie ^a   Cha, Danielle S ^a   Subramaniapillai, Mehala ^a   Lee, Yena ^a   Lovshin, Julie ^c   Lee, Jung G ^a,d   Lee, Jae Hon ^a,e   Drobinin, Vladislav ^f   Newport, Jason ^f   Brietzke, Elisa ^b   Reininghaus, Eva Z ^g   Sim, Kang ^h   Vinberg, Maj ⁱ   Rasgon, Natalie ^j   Hajek, Tomas ^f   McIntyre, Roger S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d Inje University   (South Korea)

^e Samsung Medical Center   (South Korea)

^f DALHOUSIE UNIVERSITY   (Canada)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h INSTITUTE OF MENTAL HEALTH   (Singapore)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j STANFORD UNIVERSITY   (United States)

more..

Author keywords

Glucagon like peptide 1; Gray matter volume; Liraglutide; Mood disorders; Neuroimaging; Weight loss

Indexed keywords

GLUCOSE; LIRAGLUTIDE; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ADD ON THERAPY; ADULT; AGE; AMYGDALA; ARTICLE; BIPOLAR DISORDER; BODY MASS; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DORSAL STRIATUM; DRUG DOSE TITRATION; DRUG EFFECT; EXECUTIVE FUNCTION; FEMALE; FRONTAL CORTEX; GLOBUS PALLIDUS; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MALE; MORPHOMETRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SECONDARY ANALYSIS; SEX DIFFERENCE; STRIATE CORTEX; STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT REDUCTION; WHITE MATTER; ADOLESCENT; AGONISTS; BODY WEIGHT LOSS; COGNITIVE DEFECT; COMPLICATION; CORPUS STRIATUM; DIAGNOSTIC IMAGING; FRONTAL LOBE; IMAGE PROCESSING; MIDDLE AGED; MOOD DISORDER; OUTCOME ASSESSMENT; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; COGNITION DISORDERS; CORPUS STRIATUM; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIRAGLUTIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOOD DISORDERS; NUCLEUS ACCUMBENS; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; STATISTICS AS TOPIC; WEIGHT LOSS; YOUNG ADULT;

EID: 85028565252     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2017.08.433     Document Type: Article

References (97)

1. Abbas, T., Faivre, E., Holscher, C., Impairment of synaptic plasticity and memory formation in GLP−1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205 (2009), 265–271.
2. Alosco, M.L., Galioto, R., Spitznagel, M.B., Strain, G., Devlin, M., Cohen, R., Crosby, R.D., Mitchell, J.E., Gunstad, J., Cognitive function after bariatric surgery: evidence for improvement 3 years after surgery. Am. J. Surg. 207 (2014), 870–876.
3. Alvarez, E., Martinez, M.D., Roncero, I., Chowen, J.A., Garcia-Cuartero, B., Gispert, J.D., Sanz, C., Vazquez, P., Maldonado, A., de Caceres, J., Desco, M., Pozo, M.A., Blazquez, E., The expression of GLP−1 receptor mRNA and protein allows the effect of GLP−1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92 (2005), 798–806.
4. Araque Caballero, M.A., Kloppel, S., Dichgans, M., Ewers, M., Alzheimer's Disease Neuroimaging, I., Spatial patterns of longitudinal gray matter change as predictors of concurrent cognitive decline in amyloid positive healthy subjects. J Alzheimers Dis. 55 (2017), 343–358.
5. Arts, B., Jabben, N., Krabbendam, L., van Os, J., Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol. Med. 38 (2008), 771–785.
6. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., Wikstrom, L., Peptide hormone exendin−4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338.
7. Bettcher, B.M., Mungas, D., Patel, N., Elofson, J., Dutt, S., Wynn, M., Watson, C.L., Stephens, M., Walsh, C.M., Kramer, J.H., Neuroanatomical substrates of executive functions: beyond prefrontal structures. Neuropsychologia 85 (2016), 100–109.
8. Bond, D.J., Lang, D.J., Noronha, M.M., Kunz, M., Torres, I.J., Su, W., Honer, W.G., Lam, R.W., Yatham, L.N., The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol. Psychiatry 70 (2011), 381–387.
9. Bora, E., Yucel, M., Pantelis, C., Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 113 (2009), 1–20.
10. Bosco, D., Fava, A., Plastino, M., Montalcini, T., Pujia, A., Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell Mol. Med. 15 (2011), 1807–1821.
11. Bourne, C., Aydemir, O., Balanza-Martinez, V., Bora, E., Brissos, S., Cavanagh, J.T., Clark, L., Cubukcuoglu, Z., Dias, V.V., Dittmann, S., Ferrier, I.N., Fleck, D.E., Frangou, S., Gallagher, P., Jones, L., Kieseppa, T., Martinez-Aran, A., Melle, I., Moore, P.B., Mur, M., Pfennig, A., Raust, A., Senturk, V., Simonsen, C., Smith, D.J., Bio, D.S., Soeiro-de-Souza, M.G., Stoddart, S.D., Sundet, K., Szoke, A., Thompson, J.M., Torrent, C., Zalla, T., Craddock, N., Andreassen, O.A., Leboyer, M., Vieta, E., Bauer, M., Worhunsky, P.D., Tzagarakis, C., Rogers, R.D., Geddes, J.R., Goodwin, G.M., Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 128 (2013), 149–162.
12. Bove, R.M., Brick, D.J., Healy, B.C., Mancuso, S.M., Gerweck, A.V., Bredella, M.A., Sherman, J.C., Miller, K.K., Metabolic and endocrine correlates of cognitive function in healthy young women. Obesity 21 (2013), 1343–1349.
13. Brooks, J.O. 3rd, Bearden, C.E., Hoblyn, J.C., Woodard, S.A., Ketter, T.A., Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder. Bipolar Disord. 12 (2010), 866–874.
14. Christensen, M., Sparre-Ulrich, A.H., Hartmann, B., Grevstad, U., Rosenkilde, M.M., Holst, J.J., Vilsboll, T., Knop, F.K., Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int. J Obes. 39 (2015), 1651–1654.
15. Collette, F., Hogge, M., Salmon, E., Van der Linden, M., Exploration of the neural substrates of executive functioning by functional neuroimaging. Neuroscience 139 (2006), 209–221.
16. Daniele, G., Iozzo, P., Molina-Carrion, M., Lancaster, J., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., Gastaldelli, A., Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes, 2015.
17. Davies, M.J., Bain, S.C., Atkin, S.L., Rossing, P., Scott, D., Shamkhalova, M.S., Bosch-Traberg, H., Syren, A., Umpierrez, G.E., Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39 (2016), 222–230.
18. Depp, C.A., Strassnig, M., Mausbach, B.T., Bowie, C.R., Wolyniec, P., Thornquist, M.H., Luke, J.R., McGrath, J.A., Pulver, A.E., Patterson, T.L., Harvey, P.D., Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disord. 16 (2014), 422–431.
19. Desikan, R.S., Segonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., Buckner, R.L., Dale, A.M., Maguire, R.P., Hyman, B.T., Albert, M.S., Killiany, R.J., An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31 (2006), 968–980.
20. Diener, C., Kuehner, C., Brusniak, W., Ubl, B., Wessa, M., Flor, H., A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. Neuroimage 61 (2012), 677–685.
21. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J., Haile, C.N., Glucagon-like peptide−1 receptor is involved in learning and neuroprotection. Nat. Med. 9 (2003), 1173–1179.
22. Eack, S.M., Hogarty, G.E., Cho, R.Y., Prasad, K.M., Greenwald, D.P., Hogarty, S.S., Keshavan, M.S., Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch. Gen. Psychiatry 67 (2010), 674–682.
23. Farr, O.M., Sofopoulos, M., Tsoukas, M.A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., Ko, B.J., Liakou, C., Kanyuch, N., Tseleni-Balafouta, S., Mantzoros, C.S., GLP−1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP−1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 59 (2016), 954–965.
24. Favre, P., Baciu, M., Pichat, C., De Pourtales, M.A., Fredembach, B., Garcon, S., Bougerol, T., Polosan, M., Modulation of fronto-limbic activity by the psychoeducation in euthymic bipolar patients. A functional MRI study. Psychiatry Res. 214 (2013), 285–295.
25. Fernandez-Corcuera, P., Salvador, R., Monte, G.C., Salvador Sarro, S., Goikolea, J.M., Amann, B., Moro, N., Sans-Sansa, B., Ortiz-Gil, J., Vieta, E., Maristany, T., McKenna, P.J., Pomarol-Clotet, E., Bipolar depressed patients show both failure to activate and failure to de-activate during performance of a working memory task. J. Affect. Disord. 148 (2013), 170–178.
26. Garcia-Garcia, I., Jurado, M.A., Garolera, M., Segura, B., Marques-Iturria, I., Pueyo, R., Vernet-Vernet, M., Sender-Palacios, M.J., Sala-Llonch, R., Ariza, M., Narberhaus, A., Junque, C., Functional connectivity in obesity during reward processing. Neuroimage 66C (2012), 232–239.
27. Gault, V.A., Holscher, C., GLP−1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J Pharmacol. 587 (2008), 112–117.
28. Gault, V.A., Porter, W.D., Flatt, P.R., Holscher, C., Actions of exendin−4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J Obes. 34 (2010), 1341–1344.
29. Geijselaers, S.L., Sep, S.J., Stehouwer, C.D., Biessels, G.J., Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol, 2014.
30. Gejl, M., Egefjord, L., Lerche, S., Vang, K., Bibby, B.M., Holst, J.J., Mengel, A., Moller, N., Rungby, J., Brock, B., Gjedde, A., Glucagon-like peptide−1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb. Blood Flow. Metab. 32 (2012), 2146–2152.
31. Gejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S.B., Vang, K., Rodell, A., Braendgaard, H., Gottrup, H., Schacht, A., Moller, N., Brock, B., Rungby, J., In Alzheimer's disease, 6-month treatment with GLP−1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci., 8, 2016, 108.
32. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Holscher, C., Val(8)GLP−1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33 (2012), 265–276.
33. Gluck, M.E., Ziker, C., Schwegler, M., Thearle, M., Votruba, S.B., Krakoff, J., Impaired glucose regulation is associated with poorer performance on the Stroop Task. Physiol. Behav. 122 (2013), 113–119.
34. Gunstad, J., Lhotsky, A., Wendell, C.R., Ferrucci, L., Zonderman, A.B., Longitudinal examination of obesity and cognitive function: results from the Baltimore longitudinal study of aging. Neuroepidemiology 34 (2010), 222–229.
35. Gunstad, J., Paul, R.H., Cohen, R.A., Tate, D.F., Spitznagel, M.B., Gordon, E., Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr. Psychiatry 48 (2007), 57–61.
36. Hajek, T., Calkin, C., Blagdon, R., Slaney, C., Alda, M., Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol. Psychiatry, 2013.
37. Hajek, T., Calkin, C., Blagdon, R., Slaney, C., Uher, R., Alda, M., Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology 39 (2014), 2910–2918.
38. Hamilton, A., Patterson, S., Porter, D., Gault, V.A., Holscher, C., Novel GLP−1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci. Res. 89 (2011), 481–489.
39. Honea, R.A., Szabo-Reed, A.N., Lepping, R.J., Perea, R., Breslin, F., Martin, L.E., Brooks, W.M., Donnelly, J.E., Savage, C.R., Voxel-based morphometry reveals brain gray matter volume changes in successful dieters. Obesity 24 (2016), 1842–1848.
40. Hunter, K., Holscher, C., Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13, 2012, 33.
41. Ishoy, P.L., Fagerlund, B., Broberg, B.V., Bak, N., Knop, F.K., Glenthoj, B.Y., Ebdrup, B.H., No cognitive-enhancing effect of GLP−1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. Acta Psychiatr. Scand, 2017.
42. Karlamangla, A.S., Miller-Martinez, D., Lachman, M.E., Tun, P.A., Koretz, B.K., Seeman, T.E., Biological correlates of adult cognition: midlife in the United States (MIDUS). Neurobiol. Aging 35 (2014), 387–394.
43. Karunakaran, U., Park, K.G., A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diabetes Metab. J 37 (2013), 106–112.
44. Kastin, A.J., Akerstrom, V., Pan, W., Interactions of glucagon-like peptide−1 (GLP−1) with the blood-brain barrier. J Mol. Neurosci. 18 (2002), 7–14.
45. Katsurada, K., Maejima, Y., Nakata, M., Kodaira, M., Suyama, S., Iwasaki, Y., Kario, K., Yada, T., Endogenous GLP−1 acts on paraventricular nucleus to suppress feeding: projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin−1 and oxytocin neurons. Biochem. Biophys. Res. Commun. 451 (2014), 276–281.
46. Kenna, H., Hoeft, F., Kelley, R., Wroolie, T., DeMuth, B., Reiss, A., Rasgon, N., Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol. Aging 34 (2013), 641–649.
47. Khera, R., Murad, M.H., Chandar, A.K., Dulai, P.S., Wang, Z., Prokop, L.J., Loomba, R., Camilleri, M., Singh, S., Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315 (2016), 2424–2434.
48. Kullmann, S., Heni, M., Veit, R., Ketterer, C., Schick, F., Haring, H.U., Fritsche, A., Preissl, H., The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum. Brain Mapp. 33 (2012), 1052–1061.
49. Kuswanto, C.N., Sum, M.Y., Yang, G.L., Nowinski, W.L., McIntyre, R.S., Sim, K., Increased body mass index makes an impact on brain white-matter integrity in adults with remitted first-episode mania. Psychol. Med., 2013, 1–9.
50. Lee, R.S., Hermens, D.F., Porter, M.A., Redoblado-Hodge, M.A., A meta-analysis of cognitive deficits in first-episode major depressive disorder. J. Affect. Disord. 140 (2012), 113–124.
51. Leong, R.L., Lo, J.C., Sim, S.K., Zheng, H., Tandi, J., Zhou, J., Chee, M.W., Longitudinal brain structure and cognitive changes over 8 years in an East Asian cohort. Neuroimage 147 (2017), 852–860.
52. Levy, J.C., Matthews, D.R., Hermans, M.P., Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998), 2191–2192.
53. Li, C.T., Hsieh, J.C., Wang, S.J., Yang, B.H., Bai, Y.M., Lin, W.C., Lan, C.C., Su, T.P., Differential relations between fronto-limbic metabolism and executive function in patients with remitted bipolar I and bipolar II disorder. Bipolar Disord. 14 (2012), 831–842.
54. Mann-Wrobel, M.C., Carreno, J.T., Dickinson, D., Meta-analysis of neuropsychological functioning in euthymic bipolar disorder: an update and investigation of moderator variables. Bipolar Disord. 13 (2011), 334–342.
55. Mansur, R.B., Ahmed, J., Cha, D.S., Woldeyohannes, H.O., Subramaniapillai, M., Lovshin, J., Lee, J.G., Lee, J.H., Brietzke, E., Reininghaus, E.Z., Sim, K., Vinberg, M., Rasgon, N., Hajek, T., McIntyre, R.S., Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J. Affect. Disord. 207 (2016), 114–120.
56. Maritim, A.C., Sanders, R.A., Watkins, J.B. 3rd, Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 (2003), 24–38.
57. McClean, P.L., Parthsarathy, V., Faivre, E., Holscher, C., The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31 (2011), 6587–6594.
58. McCrimmon, R.J., Ryan, C.M., Frier, B.M., Diabetes and cognitive dysfunction. Lancet 379 (2012), 2291–2299.
59. McIntyre, R.S., A vision for drug discovery and development: novel targets and multilateral partnerships. Adv. Ther. 31 (2014), 245–246.
60. McIntyre, R.S., Cha, D.S., Soczynska, J.K., Woldeyohannes, H.O., Gallaugher, L.A., Kudlow, P., Alsuwaidan, M., Baskaran, A., Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression Anxiety 30 (2013), 515–527.
61. McIntyre, R.S., Vagic, D., Swartz, S.A., Soczynska, J.K., Woldeyohannes, H.O., Voruganti, L.P., Konarski, J.Z., Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. CNS Drugs 22 (2008), 443–453.
62. Miskowiak, K.W., Macoveanu, J., Vinberg, M., Assentoft, E., Randers, L., Harmer, C.J., Ehrenreich, H., Paulson, O.B., Knudsen, G.M., Siebner, H.R., Kessing, L.V., Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders. Acta Psychiatr. Scand. 134 (2016), 249–259.
63. Miskowiak, K.W., Vinberg, M., Macoveanu, J., Ehrenreich, H., Koster, N., Inkster, B., Paulson, O.B., Kessing, L.V., Skimminge, A., Siebner, H.R., Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol. Psychiatry 78 (2015), 270–277.
64. Nazaribadie, M., Amini, M., Ahmadpanah, M., Asgari, K., Jamlipaghale, S., Nazaribadie, S., Executive functions and information processing in patients with type 2 diabetes in comparison to pre-diabetic patients. J. Diabetes Metab. Disord., 13, 2014, 27.
65. Niendam, T.A., Laird, A.R., Ray, K.L., Dean, Y.M., Glahn, D.C., Carter, C.S., Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cogn. Affect Behav. Neurosci. 12 (2012), 241–268.
66. Ostawal, A., Mocevic, E., Kragh, N., Xu, W., Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther. 7 (2016), 411–438.
67. Parkinson, J.R., Chaudhri, O.B., Kuo, Y.T., Field, B.C., Herlihy, A.H., Dhillo, W.S., Ghatei, M.A., Bloom, S.R., Bell, J.D., Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP−1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 44 (2009), 1022–1031.
68. Phillips, M.L., Swartz, H.A., A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am. J Psychiatry, 2014.
69. Porter, D.W., Kerr, B.D., Flatt, P.R., Holscher, C., Gault, V.A., Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. 12 (2010), 891–899.
70. Prehn, K., Jumpertz von Schwartzenberg, R., Mai, K., Zeitz, U., Witte, A.V., Hampel, D., Szela, A.M., Fabian, S., Grittner, U., Spranger, J., Floel, A., Caloric restriction in older adults-differential effects of weight loss and reduced weight on brain structure and function. Cereb. Cortex, 2016.
71. Reagan, L.P., Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp. Neurol. 233 (2012), 68–78.
72. Reuter, M., Fischl, B., Avoiding asymmetry-induced bias in longitudinal image processing. Neuroimage 57 (2011), 19–21.
73. Reuter, M., Schmansky, N.J., Rosas, H.D., Fischl, B., Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 61 (2012), 1402–1418.
74. Richard, J.E., Farkas, I., Anesten, F., Anderberg, R.H., Dickson, S.L., Gribble, F.M., Reimann, F., Jansson, J.O., Liposits, Z., Skibicka, K.P., GLP−1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: neuroanatomical, electrophysiological, and behavioral evidence. Endocrinology 155 (2014), 4356–4367.
75. Rinaman, L., Interoceptive stress activates glucagon-like peptide−1 neurons that project to the hypothalamus. Am. J Physiol. 277 (1999), R582–R590.
76. Samaras, K., Lutgers, H.L., Kochan, N.A., Crawford, J.D., Campbell, L.V., Wen, W., Slavin, M.J., Baune, B.T., Lipnicki, D.M., Brodaty, H., Trollor, J.N., Sachdev, P.S., The impact of glucose disorders on cognition and brain volumes in the elderly: the Sydney memory and ageing study. Age 36 (2014), 977–993.
77. Sanz, C.M., Ruidavets, J.B., Bongard, V., Marquie, J.C., Hanaire, H., Ferrieres, J., Andrieu, S., Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care 36 (2013), 1512–1521.
78. Schlogl, H., Kabisch, S., Horstmann, A., Lohmann, G., Muller, K., Lepsien, J., Busse-Voigt, F., Kratzsch, J., Pleger, B., Villringer, A., Stumvoll, M., Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 36 (2013), 1933–1940.
79. Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sorensen, J., Cowley, M.A., Dalboge, L.S., Hansen, G., Grove, K.L., Pyke, C., Raun, K., Schaffer, L., Tang-Christensen, M., Verma, S., Witgen, B.M., Vrang, N., Bjerre Knudsen, L., The arcuate nucleus mediates GLP−1 receptor agonist liraglutide-dependent weight loss. J. Clin. Investig. 124 (2014), 4473–4488.
80. Siervo, M., Arnold, R., Wells, J.C., Tagliabue, A., Colantuoni, A., Albanese, E., Brayne, C., Stephan, B.C., Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes. Rev. 12 (2011), 968–983.
81. Snyder, H.R., Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol. Bull. 139 (2013), 81–132.
82. Strakowski, S.M., Adler, C.M., Almeida, J., Altshuler, L.L., Blumberg, H.P., Chang, K.D., DelBello, M.P., Frangou, S., McIntosh, A., Phillips, M.L., Sussman, J.E., Townsend, J.D., The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 14 (2012), 313–325.
83. Sun, D., Zhang, J., Fan, Y., Liu, X., Gao, Y., Wu, G., Yan, Y., Zeng, J., Abnormal levels of brain metabolites may mediate cognitive impairment in stroke-free patients with cerebrovascular risk factors. Age Ageing 43 (2014), 681–686.
84. Tanaka, K., Saisho, Y., Manesso, E., Tanaka, M., Meguro, S., Irie, J., Sugiura, H., Kawai, T., Jinzaki, M., Cobelli, C., Itoh, H., Investigators, K.-L.S., Effects of liraglutide monotherapy on beta cell function and pancreatic enzymes compared with metformin in Japanese overweight/obese patients with type 2 diabetes mellitus: a subpopulation analysis of the KIND-LM randomized trial. Clin. Drug Investig. 35 (2015), 675–684.
85. Taylor, V.H., MacQueen, G.M., Cognitive dysfunction associated with metabolic syndrome. Obes. Rev. 8 (2007), 409–418.
86. Tran, B., Oliver, S., Rosa, J., Galassetti, P., Aspects of inflammation and oxidative stress in pediatric obesity and type 1 diabetes: an overview of ten years of studies. Exp. Diabetes Res., 2012, 2012, 683680.
87. Trudeau, F., Gagnon, S., Massicotte, G., Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur. J Pharmacol. 490 (2004), 177–186.
88. Tse, S., Chan, S., Ng, K.L., Yatham, L.N., Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 16 (2014), 217–229.
89. Tuulari, J.J., Karlsson, H.K., Antikainen, O., Hirvonen, J., Pham, T., Salminen, P., Helmio, M., Parkkola, R., Nuutila, P., Nummenmaa, L., Bariatric surgery induces white and grey matter density recovery in the morbidly obese: a voxel-based morphometric study. Hum. Brain Mapp, 2016.
90. van Bloemendaal, L., RG, I.J., Ten Kulve, J.S., Barkhof, F., Konrad, R.J., Drent, M.L., Veltman, D.J., Diamant, M., GLP−1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63 (2014), 4186–4196.
91. Verdich, C., Flint, A., Gutzwiller, J.P., Naslund, E., Beglinger, C., Hellstrom, P.M., Long, S.J., Morgan, L.M., Holst, J.J., Astrup, A., A meta-analysis of the effect of glucagon-like peptide−1 (7−36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86 (2001), 4382–4389.
92. Wang, X.H., Li, L., Holscher, C., Pan, Y.F., Chen, X.R., Qi, J.S., Val8-glucagon-like peptide−1 protects against Abeta1−40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170 (2010), 1239–1248.
93. Watari, K., Letamendi, A., Elderkin-Thompson, V., Haroon, E., Miller, J., Darwin, C., Kumar, A., Cognitive function in adults with type 2 diabetes and major depression. Arch. Clin. Neuropsychol. 21 (2006), 787–796.
94. Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M.E., Hollenberg, A.N., Baggio, L., Saper, C.B., Drucker, D.J., Elmquist, J.K., Glucagon-like peptide−1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Investig. 110 (2002), 43–52.
95. Yim, C.Y., Soczynska, J.K., Kennedy, S.H., Woldeyohannes, H.O., Brietzke, E., McIntyre, R.S., The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur. Psychiatry 27 (2012), 223–228.
96. Yogi-Morren, D., Galioto, R., Strandjord, S.E., Kennedy, L., Manroa, P., Kirwan, J.P., Kashyap, S., Gunstad, J., Duration of type 2 diabetes and very low density lipoprotein levels are associated with cognitive dysfunction in metabolic syndrome. Cardiovasc. Psychiatry Neurol., 2014, 2014, 656341.
97. Zhang, Y., Ji, G., Xu, M., Cai, W., Zhu, Q., Qian, L., Zhang, Y.E., Yuan, K., Liu, J., Li, Q., Cui, G., Wang, H., Zhao, Q., Wu, K., Fan, D., Gold, M.S., Tian, J., Tomasi, D., Liu, Y., Nie, Y., Wang, G.J., Recovery of brain structural abnormalities in morbidly obese patients after bariatric surgery. Int. J Obes, 2016.